Placeholder Banner

BIO Announces 2019 Start-up Stadium Winners

The Biotechnology Innovation Organization (BIO) today announced winners of the Start-up Stadium competition held last month at the BIO International Convention in Philadelphia. 

July 1, 2019
Media Contact
Theresa Brady
202.962.9235

Washington, DC – (July 1, 2019) – The Biotechnology Innovation Organization (BIO) today announced winners of the Start-up Stadium competition held last month at the BIO International Convention in Philadelphia. During five sessions over three days, live presentations of 50 finalists were evaluated by expert judges with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors. One winner was chosen for each session. From 13 countries and 24 US states, competitors were judged on the strength of their commercially viable cutting-edge technologies and therapeutic solutions.

The winners are:

“The benefits of participating in the Start-up Stadium competition go beyond winning a contest,” said Nareg Sagherian, BIO’s Director of Investor Relations & Programming. “According to our surveys, even the companies that don’t win have been approached by investors who were either judges or audience participants listening to their presentation. These are opportunities that participating companies may not have had otherwise, and we are pleased with the enormous success of this interactive experience.”

Winning companies receive a one-year membership in BIO, a one-hour advisory discussion with two venture capital firms (Hemi Ventures and Wells Fargo Strategic Capital) and will be fast-tracked into the final selection phase for up to a $75,000 convertible note as part of the Delaware Innovation Space’s First Fund program.

A full list of 2019 participants and judges can be found here.

Discover More
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…
July 17, 2024 – BIO President and CEO John F. Crowley today released the following statement after the U.S. Food & Drug Administration (FDA) announced a plan to establish a Rare Disease Innovation Hub that will utilize new and collaborative…
BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating…